- Tumors1000+
- Cancer1000+
- Pathologic Processes1000+
- Pathology1000+
- Immune System Diseases927
Any
<10 miles
<30 miles
<50 miles
<70 miles
Filter Results
Condition
- Tumors1000+
- Cancer1000+
- Pathologic Processes1000+
- Pathology1000+
- Immune System Diseases927
Where are you looking?
How far are you willing to travel?Any
How old are you?
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
- HER2 negative
- ER positive
- HER2 positive
- PD-L1 positive
- PR positive
- PR negative
- ER negative
- PD-L1 negative
- EGFR positive
- EGFR negative
- KRAS positive
- BRAF positive
- ALK negative
- CD20 positive
- BRCA1 positive
- BRCA2 positive
- p16 positive
- CD19 positive
- HLA-A positive
- IDH positive
- BRAF negative
- HLA positive
- ALK positive
- MYC positive
- MET positive
- HR positive
- TP53 positive
- HLA negative
- ROS1 negative
- CD5 positive
- p16 negative
- HLA-A negative
- HPV positive
- PIK3CA positive
- CCND1 positive
- NRAS positive
- RB1 positive
- RET positive
- BCL2 positive
- IDH negative
- RB1 negative
- ROS1 positive
- FLT3 positive
- HPV negative
- MET negative
- NF1 positive
- RAS positive
- BCL6 positive
- BRCA positive
- MSI-H positive
- PALB2 positive
- ANA positive
- BCR-ABL1 positive
- CD30 positive
- HBsAg positive
- KRAS negative
- L858R positive
- MMR positive
- ctDNA positive
- dMMR positive
- ex19del positive
- t(11;14) positive
- MSS positive
- RAS negative
- RET negative
- TP53 negative
- anti-dsDNA positive
- p53 positive
- BRCA1 negative
- FGFR2 positive
- FLT3 negative
- NF2 positive
- NRAS negative
- Philadelphia chromosome negative
- SMN1 positive
- ARID1A positive
- BRCA2 negative
- CD19 negative
- CD4 positive
- CLDN18.2 positive
- COL7A1 positive
- HBV DNA positive
- Ki-67 positive
- MGMT negative
- MMR negative
- MSI positive
- MSI-H negative
- NTRK negative
- PTEN positive
- Philadelphia chromosome positive
- RF positive
- T790M positive
- TERT positive
- TTR positive
- dMMR negative
- 17p deletion positive
- ABCA4 positive
- ATM positive
- BRCA negative
- CD123 positive
- CD20 negative
- CD23 positive
- CFTR positive
- EBV positive
- FGFR3 positive
- HBsAg negative
- HR negative
- HRD positive
- KIT positive
- MDM2 positive
- MGMT positive
- MLH1 positive
- MSH2 positive
- MSH6 positive
- NTRK positive
- PMS2 positive
- Ph positive
- RAF positive
- SMN2 positive
- TMB positive
- TROP2 negative
- TROP2 positive
- bcr-abl positive
- t(9;22) positive
- APP positive
- BRIP1 positive
- C5 positive
- CDK12 positive
- CDK4 positive
- CHEK2 positive
- EPCAM positive
- FANCA positive
- FMR1 positive
- FVIII positive
- GRN positive
- HBB positive
- HBV DNA negative
- HRAS positive
- HbSS positive
- Hepatitis B DNA negative
- IL2RG positive
- JAK2 positive
- MSI negative
- MYC negative
- MYD88 L265P positive
- NF1 negative
- PD-1 negative
- PD-1 positive
- PML-RARA negative
- PSEN1 positive
- PSEN2 positive
- RAD51 positive
- RUNX1 positive
- SMARCB1 negative
- SPINK5 positive
- STK11 positive
- anti-AChR positive
- anti-Ro autoantibodies positive
- anti-Ro/SSA positive
- anti-Sm positive
- del(17p) positive
- pMMR positive
- t(11;14)(q13;q32) positive
- β-thalassemia positive
- 11q negative
- 11q positive
- 19q negative
- 1p negative
- AChR positive
- AKT negative
- ALPL positive
- ALT positive
- APOL1 positive
- ASXL1 positive
- ATRX negative
- ATRX positive
- Anti-Smith positive
- Aβ1-42 positive
- BAP1 positive
- BARD1 positive
- BCR/ABL negative
- BCR/ABL positive
- BCR::ABL1 positive
- C9orf72 positive
- CCND1 negative
- CCND2 positive
- CCND3 positive
- CD22 positive
- CD3 positive
- CD30 negative
- CD4 count positive
- CD5 negative
- CD8 positive
- CDK6 positive
- CEACAM5 positive
- CHEK1 positive
- COL1A1 positive
- COL1A2 positive
- CRLF2 positive
- CTC1 positive
- Gleason Score 10
- Gleason Score 6
- Gleason Score 7
- Gleason Score 8
- Gleason Score 9
- Grade 1
- Grade 2
- Grade 3
- Grade 4
- Stage IV
- Stage III
- Stage II
- Stage I
- 1 Prior Chemotherapy Regimen for Metastatic Disease
- 1927nm Fractional Thulium Laser Treatment
- >= 2 Bone Metastases (Untreated Lesion)
- ALK TKI Therapy
- ANC >= 1,500/mcL
- AST/ALT =< 3 x ULN
- Activating EGFR mutation [exon 19 deletion or exon 21 (L858R) substitution mutation]
- Active Treatment for Cutaneous Squamous Cell Carcinoma
- Active Treatment for Non-Invasive Basal Cell Carcinoma
- Adjuvant Radiation for 4-6 weeks
Trial Status
Recruiting statusPlacebo
Recruiting
Waitlist Available
Administration Type
Trial Phase
Biomarkers
Stage of Disease
6830 trials
Trials Without a Placebo
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial aims to see if bitopertin is effective and safe in treating EPP or XLP in participants aged 12 and above. It will investigate whether bitopertin can increase pain
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Waitlist
Phase 2 & 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial aims to compare the effects of different types of fluids given during surgery on acid-base balance and electrolytes in young patients. Patients will be randomly assigned to receive either normal saline or hypertonic saline
Efficacy & Safety Awards
No Placebo-Only Group
Columbus, OH (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
Summary"This trial aims to test a combination of interventions, including improving sleep, cognitive exercises, and extended pain relief after heart surgery to reduce confusion, agitation, and decline in cognitive function. These interventions are based
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
Summary"This trial will test a new long-acting HIV treatment for people who still have detectable virus levels despite taking oral medication. The study will look at how well the treatment works, how safe it is
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing whether giving azithromycin along with standard antibiotics to 8,000 women having a cesarean delivery can help reduce infections after childbirth. The study will compare the rates of
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial will randomly assign participants to receive either Luminopia dichoptic treatment, Vivid Vision dichoptic treatment, or continued optical correction alone. Participants will be assessed at 9 and 18 weeks
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial compares two types of radiation therapy for treating cancer that has spread to the brain. One type, called fractionated stereotactic radiosurgery (FSRS), delivers a high dose of radiation over
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
Summary"This trial aims to see if barzolvolimab is effective, safe, and well-tolerated in adults with Chronic Spontaneous Urticaria who have not responded well to common
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
Summary"This trial is comparing the effects of combining immunotherapy (pembrolizumab) with chemotherapy (doxorubicin) versus using chemotherapy alone to treat patients with undifferentiated pleomorphic sar
Efficacy & Safety Awards
Pivotal Trial
No Placebo-Only Group
Get notified when new Lazy Eye trials are postedWe'll send you an email whenever new trials are posted
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial aims to compare two treatments for children aged 4 to 7 with lazy eye. One treatment involves watching special movies with a headset for 1 hour per day, 6 days a week
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test if plozasiran injection is safe and effective in adults with high triglyceride levels. Participants will receive either plozasiran or a placebo every 3 months for a
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
Summary"This trial will test a new injection called plozasiran in adults with very high levels of triglycerides. Participants will receive either plozasiran or a placebo every 3 months for a
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial will test the safety and effectiveness of plozasiran injection in adults with severe high levels of triglycerides. Participants will receive either plozasiran or a placebo every 3 months
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
Summary"This trial compares two drugs, rituximab and mosunetuzumab, in treating patients with low tumor burden follicular lymphoma. Rituximab targets a protein found on B
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing the effectiveness of ZILRETTA in reducing pain in people with glenohumeral osteoarthritis when compared to a placebo. The secondary objectives include comparing the pain
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 31 Award
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing a new drug called pelacarsen to see if it is effective and safe for Black/African American and Hispanic individuals with heart disease and high levels of Lp(a). Participants
Efficacy & Safety Awards
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial aims to compare the overall survival of patients with certain types of advanced soft tissue sarcomas who have already tried 2 standard treatments, including one with anthracycline, with a new
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Waitlist
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial will investigate the impact of a single dose of SRP-9003 on beta-sarcoglycan gene expression in individuals with limb-girdle muscular dystrophy type 2E/R
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Get notified when new Idiopathic Pulmonary Fibrosis trials are postedWe'll send you an email whenever new trials are posted
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
Summary"This trial is for people with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis who have completed treatment with a medicine called BI 1015550 in a previous study. The goal is to see how
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
Columbus, OH (<10 mi)
Recruiting
Phase 32 Awards
0 Criteria Met
Eligibility Criteria
SummaryThis trial is testing if adding a monoclonal antibody called dinutuximab to standard treatments like chemotherapy and stem cell transplantation can help treat children with a type of cancer called high risk neuroblast
Efficacy & Safety Awards
No Placebo-Only Group
Pivotal Trial
1
2
3
…50